MEDIA CENTER

PRESS RELEASES
NEWS

Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing

DELIVER Therapeutics, Inc. (“DELIVER”) a company that plans to apply novel, high-throughput screening technologies combined with chemical innovation to DELIVER therapeutics that address the most difficult problems in clinical medicine has been launched with an initial $3M Convertible Note financing by Rapha Capital BioVentures Fund I, LP

Edward Galli In News

Deliver Pharmaceuticals Presents at the 2024 Alexandria Seed Capital Platform’s Seed Catalyst Partnership Meeting

Dr. Kevin Slawin, MD, Founder, Chairman and CEO of Deliver Therapeutics, Inc., presented the company at this year’s Alexandria Seed Capital Platform’s Seed Catalyst Partnership Meeting held at The Alexandria…

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

GoodZ.Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.Nature Medicine.2018

/wp-content/uploads/2024/07/GoodZ.Single-cell-developmental-classification-of-B-cell-precursor-acute-lymphoblastic-leukemia-at-diagnosis-reveals-predictors-of-relapse.Nature-Medicine.2018.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

LeonardJ.Aurora A kinase as a target for therapy in TCF3-HLF rearranged ALL Haematologica 2021

/wp-content/uploads/2024/07/LeonardJ.Aurora-A-kinase-as-a-target-for-therapy-in-TCF3-HLF-rearranged-acute-lymphoblastic-leukemia.Haematologica.2021.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

OkabeS. Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells.Oncotarget.2018

/wp-content/uploads/2024/07/OkabeS.-Therapeutic-targeting-of-Aurora-A-kinase-in-Philadelphia-chromosome-positive-ABL-tyrosine-kinase-inhibitor-resistant-cells.Oncotarget.2018.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

RobertsKG.Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia.NEJM.2014

/wp-content/uploads/2024/07/RobertsKG.Targetable-Kinase-Activating-Lesions-in-Ph-like-Acute-Lymphoblastic-Leukemia.NEJM_.2014.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

WarschW. JAK of all trades- JAK2-STAT5 as novel therapeutic targets in BCR-ABL+ chronic myeloid leukemia.Blood.2013

/wp-content/uploads/2024/07/WarschW.-JAK-of-all-trades-JAK2-STAT5-as-novel-therapeutic-targets-in-BCR-ABL11-chronic-myeloid-leukemia.Blood_.2013.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

YuanH.Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.Carcinogenesis.2012

/wp-content/uploads/2024/07/YuanH.Overcoming-CML-acquired-resistance-by-specific-inhibition-of-Aurora-A-kinase-in-the-KCL-22-cell-model.Carcinogenesis.2012.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse

/wp-content/uploads/2024/07/FoaR.Philadelphia-Chromosome–Positive-Acute-Lymphoblastic-Leukemia.NEJM_.2022.pdf

MEDIA CENTER

Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing

Deliver Pharmaceuticals Presents at the 2024 Alexandria Seed Capital Platform’s Seed Catalyst Partnership Meeting

Archives

SCIENTIFIC PUBLICATIONS

GoodZ.Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.Nature Medicine.2018

LeonardJ.Aurora A kinase as a target for therapy in TCF3-HLF rearranged ALL Haematologica 2021

OkabeS. Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells.Oncotarget.2018

RobertsKG.Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia.NEJM.2014

WarschW. JAK of all trades- JAK2-STAT5 as novel therapeutic targets in BCR-ABL+ chronic myeloid leukemia.Blood.2013

YuanH.Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.Carcinogenesis.2012

Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse